Tongue Squamous Cell Carcinoma: Causes & Treatments

Tongue squamous cell carcinoma is the most common cancer of the oral cavity, arising from the flat cells that line the tongue’s surface. Its two leading causes are tobacco and alcohol use, which together create a risk far greater than either habit alone. Treatment typically centers on surgery, often followed by radiation or chemoradiation depending on how advanced the disease is at diagnosis. But this cancer has become more complicated to understand in recent decades, partly because it is increasingly showing up in people who have none of the traditional risk factors.

Tobacco, Alcohol, and Their Combined Effect

Tobacco use and alcohol consumption remain the dominant risk factors for squamous cell carcinoma of the tongue, as they are for most cancers in the head and neck region. Each raises risk on its own, but the critical finding from large pooled studies is that combining the two habits does not simply add the risks together. A large international pooled analysis found a greater-than-multiplicative joint effect between tobacco and alcohol use for head and neck cancer risk, meaning the combined exposure amplifies risk beyond what you would expect from stacking the individual contributions.¹ In practical terms, a heavy drinker who also smokes faces dramatically higher odds of developing oral cancer than someone who only does one or the other.

In parts of South and Southeast Asia, betel quid chewing is another major contributor. A meta-analysis found that betel quid chewing was associated with roughly an eightfold increase in the odds of developing oral potentially malignant disorders compared to non-chewers, making it one of the strongest single-exposure risk factors studied.² In the same analysis, smoking roughly quadrupled the odds and alcohol roughly doubled them, but betel quid stood out as the highest individual risk factor for precancerous oral changes.

A Puzzling Rise in Young, Non-Smoking Patients

If tobacco and alcohol explain most tongue cancer, a troubling trend does not fit the pattern. Epidemiological data from multiple countries show a rising incidence of tongue squamous cell carcinoma in people under 45, particularly women who have never smoked. A multi-institutional analysis including data from Australia, Singapore, and other centers found that the number of women under 45 diagnosed with tongue cancer increased significantly over time, while the proportion of smokers in that cohort actually decreased.³ The incidence was climbing at a significantly higher rate in females than in males.

This is not a small curiosity. It challenges the assumption that tongue cancer is primarily a disease of older men with long histories of tobacco and alcohol use. Researchers have investigated whether human papillomavirus (HPV), which drives many cancers at the back of the throat, might explain the rise. But the evidence points away from that connection for the oral tongue specifically. A review aimed at dismissing this link concluded that HPV is not associated with the recent surge in biologically aggressive oral cavity cancer in young populations, based on epidemiological, histological, and immunohistochemical arguments.⁴ The cause of the increase in young non-smokers remains genuinely unknown, which is an uncomfortable gap in the science.

Precancerous Changes on the Tongue

Tongue cancer does not always appear out of nowhere. It can be preceded by visible changes in the mouth lining, collectively called oral potentially malignant disorders. Leukoplakia, a white patch that cannot be scraped off, is one of the most studied. In a study of leukoplakia specifically on the tongue, about 8% of cases underwent malignant transformation, with an annual transformation rate of roughly 2.3%.⁵ A larger database analysis found that the five-year malignant transformation rate for oral leukoplakia was about 16%, though this varies widely depending on the population studied and the histological features of the lesion.⁶

Erythroplakia, a red velvety patch, carries a similarly elevated risk. A meta-analysis of precancerous oral disorders found that leukoplakia and erythroplakia had the highest standardized odds of progressing to oral cancer among the conditions studied.⁷ The practical implication is straightforward: any persistent white or red patch on the tongue that does not resolve within a couple of weeks warrants a dental or medical evaluation. Catching a precancerous lesion early can mean the difference between a minor excision and a major cancer operation.

Genetic Changes Driving the Cancer

At the molecular level, tongue squamous cell carcinoma is driven by mutations in a handful of key genes. The most frequently altered is TP53, a well-known tumor suppressor. A genomic study of over 200 tongue cancer specimens found that TP53 carried mutations in about 63% of cases, making it the single most common genetic change.⁸ Other recurrently mutated genes include NOTCH1, CDKN2A, FAT1, and CASP8. Interestingly, the genetic landscape of tongue cancer is not identical to other head and neck cancers. A separate genomic analysis found that tongue cancers had frequent mutations in genes like DST and RNF213, while changes in CDKN2A and NOTCH1 were less common than in head and neck tumors at other sites. Alterations affecting the Notch signaling pathway turned out to be prognostic, meaning their presence was associated with different survival outcomes.⁹

The tumor does not just accumulate mutations in isolation. It shapes the environment around it. The tissue immediately surrounding the cancer, called the tumor microenvironment, contains immune cells, fibroblasts, and structural proteins that collectively influence how the cancer grows, evades the immune system, and resists treatment.¹⁰ One mechanism involves a signaling molecule called CCL22, produced by immune cells that the tumor recruits. CCL22 attracts regulatory T cells into the tumor’s vicinity, which dampen the body’s immune response and help the cancer avoid destruction.¹¹ Understanding these immune evasion tactics is part of what has driven interest in immunotherapy for this cancer.

Diagnosis and Staging

Any suspicious lesion on the tongue is ultimately confirmed by biopsy and microscopic examination. A retrospective study of tongue cancers found that the average age at diagnosis was about 56, with roughly two-thirds of cases diagnosed in people in their 50s and 60s. Men were slightly more affected. Two-thirds of cases arose in the mobile portion of the tongue, the front two-thirds you can see and move, rather than the base of the tongue at the back. The most common microscopic type was conventional squamous cell carcinoma, and the majority of cases were diagnosed at stage II or III.¹²

Staging in recent years has placed increasing emphasis on depth of invasion, meaning how deep into the tongue tissue the tumor extends. This matters because deeper tumors are more likely to spread to lymph nodes in the neck. MRI is the primary imaging tool for measuring this depth before surgery. A study using specialized MRI sequences found very strong correlation with the actual pathological depth, with the ability to correctly classify T stage in about 87% of patients.¹³ MRI does tend to slightly overestimate the depth, by roughly 2 mm on average according to a meta-analysis, partly because inflammation around the tumor can look like tumor on imaging, and partly because tissue shrinks when it is preserved after removal.¹⁴ That overestimation can occasionally bump a patient into a higher stage category than they would be assigned after surgery, but it is a known bias that surgeons account for.

Surgery and the Importance of Margins

Surgery is the primary treatment for tongue squamous cell carcinoma, especially when the cancer has not spread beyond the mouth. The goal is to remove the entire tumor along with a surrounding rim of normal tissue, the surgical margin. How wide that margin needs to be has been a subject of active debate. A systematic review and meta-analysis found that margins under 5 mm were associated with nearly a threefold increase in local recurrence, while margins of 5 mm or more were linked to a roughly 1.6-fold improvement in the probability of five-year survival.¹⁵

Some research has pushed further, asking whether even 5 mm is the right cutoff. One study proposed redefining a “close” margin as anything under 2.3 mm rather than the traditional 5 mm, based on finding that patients with margins between about 2.3 mm and 5 mm had local recurrence-free survival similar to those with margins above 5 mm.¹⁶ Meanwhile, a separate study found that widening the surgical margin from 10 mm to 15 mm at the planning stage led to significantly fewer involved margins after surgery and significantly lower rates of both local and regional recurrence.¹⁷ The tension between removing enough tissue to be safe and preserving enough tongue to function is one of the central challenges in treating this cancer.

Addressing the Neck Even When It Looks Clear

One of the most important treatment decisions involves the lymph nodes in the neck. Even when imaging shows no obvious spread, tongue cancer can harbor microscopic deposits in the neck nodes that are invisible on a scan. A landmark randomized trial published in the New England Journal of Medicine compared elective neck dissection, removing nodes at the time of the tongue surgery, to a wait-and-watch approach where neck surgery was performed only if cancer later appeared in the nodes. At three years, the elective surgery group had an overall survival rate of 80% compared to about 68% in the observation group, and disease-free survival was substantially better as well.¹⁸

A systematic review and meta-analysis confirmed the pattern, finding that elective neck dissection significantly reduced the risk of regional recurrence and improved disease-specific survival compared to observation, though the effect on overall survival across all pooled studies was not statistically significant.¹⁹ The practical takeaway is that for most early-stage tongue cancers, surgeons now favor treating the neck proactively. The risk of hidden disease is too high to simply watch and wait.

Radiation and Chemotherapy After Surgery

Not every patient needs additional treatment after surgery. The decision to add radiation or combined chemoradiation depends on what the pathologist finds in the removed tissue. High-risk features, such as cancer extending beyond the capsule of a lymph node, positive or very close margins, or advanced local spread, generally trigger a recommendation for postoperative treatment. A study of advanced tongue cancer found that cancer extending beyond the node capsule appeared to be a strong indication for concurrent chemoradiation, while without that finding, chemoradiation could not be shown to outperform radiation alone.²⁰

For patients with smaller tumors that have spread to just one lymph node without other adverse features, the benefit is less clear. A study comparing postoperative radiation to concurrent chemoradiation in this specific scenario found that chemoradiation improved survival in patients with T2 tumors (moderately sized) and a single positive node, but did not show a survival advantage for T1 (very small) tumors with a single positive node.²¹ These findings illustrate why treatment after surgery is not one-size-fits-all. Each patient’s surgical pathology report essentially writes the prescription for what comes next.

Immunotherapy for Recurrent or Advanced Disease

When tongue cancer comes back after initial treatment or is too advanced for surgery, systemic therapies become the mainstay. Immunotherapy, particularly immune checkpoint inhibitors, has changed the landscape for recurrent head and neck squamous cell carcinoma. An analysis comparing immunotherapy to targeted therapy in recurrent tongue cancer specifically found that immunotherapy was associated with improved overall survival and a low recurrence rate.²² This aligns with the broader shift across oncology toward harnessing the immune system rather than relying solely on traditional chemotherapy for advanced disease. The molecular work on the tumor microenvironment, including studies of how tongue cancers recruit regulatory T cells to suppress immune attacks, is feeding directly into efforts to design better immunotherapy strategies.

Reconstruction After Major Surgery

When a large portion of the tongue must be removed, reconstruction is not cosmetic. It is functional. The tongue is central to swallowing, speaking, and even breathing. Free-flap reconstruction, where tissue is transplanted from another part of the body along with its blood supply, allows the majority of patients to achieve adequate speech, swallowing, and quality of life.²³ Tissue is most commonly taken from the forearm (radial forearm flap) or the thigh (anterolateral thigh flap). A comparative study of the two approaches found that most patients recovered functional speech and the ability to eat, with about half returning to a regular diet and another third managing soft foods.²⁴ The forearm flap offered slightly better tongue flexibility, which is not surprising given its thinner, more pliable tissue.

For advanced tumors requiring major glossectomy, where most or all of the tongue is removed, outcomes are understandably more challenging. A study of patients undergoing major glossectomy for advanced tongue cancer reported two-year overall survival of 62% and disease-free survival of 61%, with about a third experiencing locoregional recurrence.²⁵ Even in these extensive cases, reconstruction aims to give patients the best possible baseline from which rehabilitation can build.

Swallowing Rehabilitation and Its Effect on Recovery

Difficulty swallowing is one of the most common and distressing consequences of tongue cancer treatment. Structured swallowing rehabilitation has consistently been shown to help. A study of patients who had undergone tongue resection found that those who completed a two-week program of daily swallowing exercises showed significant improvement in swallowing function and quality of life compared to patients who received no formal training.²⁶ A separate study confirmed the pattern and added that structured swallowing training also reduced depression and anxiety.²⁷

A randomized clinical trial of speech therapy in tongue cancer patients found a dramatic reduction in swallowing handicap scores, with the treatment group showing an improvement of about 40 points on a standardized dysphagia index. That improvement correlated with better quality of life and greater ability to eat by mouth.²⁸ The consistent message from this body of research is that formal rehabilitation is not optional or supplementary. It is a core component of cancer treatment that directly affects how well patients recover.

Dry Mouth and Long-Term Quality of Life After Radiation

Radiation to the head and neck region frequently damages the salivary glands, causing chronic dry mouth. This is not a minor inconvenience. Among patients who have completed head and neck radiation, the vast majority develop some degree of dry mouth, and about two-thirds experience it at moderate to severe levels. Beyond the physical discomfort, dry mouth was associated with difficulty eating and speaking, and many patients reported significant emotional effects including tension and depression.²⁹

The relationship between dry mouth severity and reduced quality of life has been confirmed statistically, with the correlation growing stronger over time after radiation. Patients who were more than six months out from completing radiation showed stronger correlations between dry mouth severity and quality-of-life impairment than those assessed earlier, suggesting the problem worsens or at least becomes more burdensome as time goes on.³⁰ A longitudinal study found that while most quality-of-life scores returned to baseline by three years after treatment, about 60% of oral tongue cancer patients still reported problems with dry mouth at that mark.³¹ Dry mouth is, for many patients, the longest-lasting reminder of their treatment.

What Shapes Prognosis

Survival after tongue squamous cell carcinoma depends on several interconnected factors. A study analyzing prognostic variables found that surgery and radiation were favorable prognostic factors, while tumors 20 mm or more in their vertical dimension, cancer extending beyond lymph node capsules, surgical margins of 3 mm or less, and poorly differentiated tumors were all associated with worse outcomes.³² Where the cancer sits on the tongue also matters. Cancers of the oral tongue, the mobile front part, tend to have better outcomes than cancers arising at the base of the tongue. A multivariate analysis showed that the difference in prognosis between these two locations was closely tied to differences in recurrence rates and regional lymph node spread.³³

Screening Tools and Their Limits

No widely adopted screening test exists for tongue cancer comparable to mammography for breast cancer or colonoscopy for colorectal cancer. The standard approach remains a visual and physical examination by a clinician. Autofluorescence imaging, which uses specific wavelengths of light to make abnormal tissue glow differently than healthy tissue, has emerged as a promising adjunctive technique. It has shown encouraging results in populations with high rates of oral cancer, but the technique requires subjective interpretation and depends heavily on the skill of the examiner.³⁴ In populations where oral cancer is less common, benign conditions like inflammation can trigger false positives, limiting the tool’s practical usefulness for mass screening.

A broader review of emerging screening technologies concluded that while adjunctive diagnostic aids can help identify suspicious lesions noninvasively, none currently has sufficient accuracy to serve as a standalone diagnostic tool. A biopsy remains the definitive step whenever a lesion looks suspicious.³⁵ For now, the best practical screening strategy is regular dental visits where a clinician can spot changes early, combined with prompt evaluation of any sore, patch, or lump on the tongue that persists for more than two to three weeks.